2026.03. 15 本文字数：1061，阅读时长大约2分钟 作者 | 第一财经 钱童心 近 日 ， 马 斯 克 的 脑 机 接 口 公 司 Neuralink 联 合 创 始 人 、 Science 公 司 CEO 马 克 斯 · 霍 达 克 （ Max Hodak）在一次深度访谈中大胆预测：人类首批有望活到1000岁的人可能已经出生了！ 尽管并非人类所有疾病都能被攻克，但脑机接口与人工智能的融合正以前所未有的速度推动人类走向 充满未知和无限可能的未来。 霍达克在离开Neuralink后创立了Science公司，该公司正在研发一款脑机接口产品Prima，有望帮 助盲人恢复视力。但他的愿景远不止于此。 霍达克预测，脑机接口不仅能够治疗失明等疾病并对抗认知下降和衰老，未来更有希望创造出"有意 识的机器"，引领生物技术进入非线性的加速"起飞时代"，这可以使得人类寿命发生剧变。 这意味着脑机接口的终极目标，远不止医疗康复或操控设备，而是事关"人类物种升级"，它的最终指 向是实现人类意识与数字智能的完全融合。 在硅谷，科技亿万富豪也都在寄望于用工程的方法来应对死亡问题，他们相信死亡是可以通过工程化 逆转的，而非宿命 ...

Core Viewpoint - The article discusses the advancements in brain-computer interface (BCI) technology, highlighting its potential to reshape human capabilities and even extend human life, as suggested by Max Hodak, co-founder of Neuralink and founder of Science [2][4]. Group 1: Brain-Computer Interface Technology - BCI technology has made significant breakthroughs, such as restoring vision for blind patients through retinal implants [9][12]. - Hodak emphasizes that the human brain functions similarly to a computer, processing information through neural pathways, which can be viewed as APIs for interaction with external systems [5][39]. - The potential applications of BCI range from restoring lost sensory functions to enhancing cognitive abilities and even preserving human consciousness [12][18]. Group 2: Clinical Applications and Innovations - Science, Hodak's company, has successfully conducted clinical trials that restored partial vision to over 40 patients using a small silicon chip implanted in the eye [14][15]. - The device operates by using a camera and laser projection to stimulate retinal cells, effectively bypassing damaged photoreceptors [15][26]. - Future developments may lead to higher bandwidth interfaces that allow for more complex interactions between the brain and digital systems [20][32]. Group 3: Future of BCI and Human Evolution - Hodak predicts that BCI technology will evolve to allow for direct brain-to-brain communication and enhanced human capabilities, potentially leading to a new paradigm in medicine and human enhancement [12][36]. - The integration of biological and engineering systems may result in a hybrid human form, where damaged organs are replaced with mechanical or electronic systems [12][62]. - The next generation of BCI may involve growing new neural connections rather than using electrical stimulation, which could lead to more natural and effective interfaces [62][64]. Group 4: Industry Insights and Comparisons - The BCI industry is compared to the pharmaceutical industry, suggesting that multiple companies will develop various types of interfaces tailored for specific applications [20][80]. - Hodak notes that the current BCI technology is still in its infancy, akin to the early days of personal computing, and emphasizes the need for continued innovation and belief in the technology's potential [60][62]. - The article highlights the shift in focus from traditional drug discovery to direct brain interaction, marking a significant change in medical paradigms [34][36].

Prima已帮助40多名失明患者重见光明。 作者 | 小鑫 编辑 | 小白 3月12日,Neuralink共创人Science CEO Max Hodak在采 访中说:"Science的Prima产品已帮助超过40+盲人重见 光明,结果发表在NEJM上。他还大胆地预测,在人工智 能(AI)和脑机接口(BCI)的融合和发展下,首批能够活到 1000岁的人类可能已经诞生。 ● Prima为2mm×2mm太阳能电池微型硅片, 植入失明患者视网膜下方。 · 成都华微 · 汉威科技,佳禾智能 · 普利特 · 光莆股份 ● 优刻得,泰和科技 · 盈趣科技 1. 医疗服务与临床转化场景 ● 三博脑科,国际医学,博济医药,塞力医疗,北陆药业 欧普康视 2. 消费健康与智能硬件场景 ● 倍轻松,麒盛科技,荣泰健康 3. 文娱与数字科技场景 ● 世纪华通,汤姆猫,岩山科技 4. 技术配套与产业孵化场景 ● 熵基科技,海格通信,力合科创,东方中科 免责声明： 本报告（文章）是基于上市公司的公众公司属性、以上市公司根据其法定义务公开披露的信息（包括但 不限于临时公告、定期报告和官方互动平台等）为核心依据的独立第三方研究；市值风云力求 ...

Core Insights - The article discusses the advancements and ambitions of Science Corp, particularly in the field of brain-computer interface (BCI) technology, led by CEO Max Hodak, who previously co-founded Neuralink [1][2][3] Company Overview - Science Corp was founded by Max Hodak and three former Neuralink colleagues approximately four years ago, aiming to create innovative BCI solutions [2][3] - The company is focused on generating revenue by manufacturing and selling tools for researchers, transforming expensive systems into affordable devices [3][19] Product Development - The initial commercial product, named Prima, involves a tiny computer chip implanted in the retina to restore vision for patients with late-stage macular degeneration, achieving an 80% success rate in clinical trials [4][20] - The company acquired the Prima technology from Pixium Vision and has optimized it for clinical trials, with plans to launch in Europe next summer [4][20] Future Innovations - Science Corp is exploring optogenetic gene therapy to make neurons light-sensitive, aiming to eliminate the need for electrodes in BCI applications [5][21][22] - The company is also investigating the potential to cultivate new brain tissue, which could overcome limitations associated with traditional electrode technology [7][23] Long-term Vision - Hodak envisions that BCI technology could eventually lead to the creation of conscious machines, addressing the fundamental nature of consciousness and its implications for human experience [10][24][25] - By 2035, Hodak predicts that BCI technology will be available for patients, potentially allowing for consciousness uploading as a treatment option for terminal illnesses [12][26] Economic Implications - The article highlights concerns about the economic model of healthcare as BCI technology becomes more prevalent, suggesting that it may lead to increased healthcare costs and a divide between wealthy and less affluent individuals [14][27] - Hodak argues that while consumer technology tends to become cheaper and more accessible, the healthcare sector operates under a fixed funding model that may not sustain the rising costs associated with advanced BCI technologies [14][27]